Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Denileukin diftitox: a concise clinical review.

John W Eklund1, Timothy M Kuzel

  • 1Division of Hematology/Oncology, Northwestern University, 676 North St. Clair Street, Suite 850, Chicago, IL 60611, USA. j-eklund@md.northwestern.edu

Expert Review of Anticancer Therapy
|March 11, 2005
PubMed
Summary

Denileukin diftitox is an FDA-approved fusion protein for cutaneous T-cell lymphoma. This review covers its clinical trials and potential uses in other cancers and diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual Targeting of Nucleotidase-Dependent and -Independent Functions via PROTAC-Mediated CD73 Degradation.

Journal of medicinal chemistry·2026
Same author

IL-15 Complexes Combined with PD-1 Blockade Affect Immune Cell Distribution, Localization, and Immune Signatures in Regressing Versus Non-Regressing Metastatic Breast Tumors.

International journal of molecular sciences·2025
Same author

4-1BB stimulation with concomitant inactivation of adenosine A2B receptors enhances CD8+ T cell antitumor response.

The Journal of clinical investigation·2025
Same author

Indeterminate Cell Histiocytosis and a Review of Current Treatment.

Cutis·2025
Same author

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.

International journal of molecular sciences·2024

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin's lymphoma.
  • Relapsed or refractory CTCL presents significant treatment challenges.

Purpose of the Study:

  • To review clinical trials for denileukin diftitox (DAB389IL-2; Ontak) in CTCL.
  • To discuss the potential of denileukin diftitox in other malignant and nonmalignant diseases.

Main Methods:

  • Review of clinical trial data for denileukin diftitox.
  • Analysis of drug mechanism targeting the interleukin-2 receptor.

Main Results:

  • Denileukin diftitox is approved for relapsed/refractory CTCL.
  • The drug targets malignant cells expressing the high-affinity interleukin-2 receptor.

Conclusions:

  • Denileukin diftitox represents a novel therapeutic option for CTCL.
  • Further investigation into its use for non-Hodgkin's lymphoma, leukemia, solid tumors, psoriasis, and graft-versus-host disease is warranted.

Related Experiment Videos